Nichole Tucker

The FDA has granted approval lisocabtagene maraleucel for the treatment of adult patients with large B-cell lymphoma, with specific indications for patients with relapsed or refractory disease.

Results from a study of tazemetostat in patients with BAP1-inactivated malignant pleural mesothelioma show the feasibility of molecularly-stratified therapy for patients with relapsed or refractory disease.

Developers of elacestrant are seeking FDA approval of the agent for the treatment of patients with ER-positive/HER2-negative advanced or metastatic breast cancer.

In an interview with Targeted Oncology, Leonard A. Kalman, MD, discussed how real-world data will improve the understanding of patients with cancer being treated at Miami Cancer Institute and of how the business runs overall.

An investigational bivalent gB/pp65 immunotherapeutic vaccine candidate has been granted orphan drug designation by the FDA for the treatment of patients with glioblastoma.

The FDA has granted orphan drug designation to MB-106, for the treatment of patients with Waldenstrom macroglobulinemia. The agent is being investigated in a phase 1/2 clinical trial.

Alexander Drilon, MD, discussed NTRK gene fusions in solid tumors, collective findings of studies assessing larotrectinib for the treatment of these fusions, and how to conduct genomic testing to identify patients who might benefit from TRK inhibitor therapy.

In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.

On the heels of positive phase 1 data, the phase 3 TROPION-Breast02 clinical trial has begun dosing of datopotamab deruxtecan in select patients with metastatic triple-negative breast cancer.

In an interview with Targeted Oncology™, Bruce Feinberg, DO, discussed the use of CAR T-cell therapy in the community oncology setting, the challenges oncologist face, and the next wave of innovation to improve CAR T-cell administration for patients.

Continued robust quality of life improvement documented in an expanded dataset of patients with TRK fusion cancer treated with larotrectinib are consistent with the rapid onset of clinical benefit and favorable safety profile of larotrectinib in both adult and pediatric patients.

Correlations between non–small cell lung cancer the metastasizes to the brain and enriched CDKN2A/B and EGFR alterations calls for further genomic exploration of this patient population.

In patients with TRK fusion central nervous system tumors, treatment with the larotrectinib continues to show rapid and durable response and manageable toxicity.

The probability of minimal residual disease negativity and complete remission in patients who received hyper-CVAD with blinatumomab and inotuzumab is higher compared with hyper-CVAD and blinatumomab alone.

Few community practices are performing in-office infusions on CAR T-cell therapy, but due to interest from 20% of them, experts recommend stakeholder alignment to address the concerns of the oncology population.

Within 60 days, the FDA will make a decision on whether to accept the biologics license application for omidubicel as treatment for patients with blood cancers in need of an allogeneic hematopoietic stem cell transplant.

A fast track designation has been granted by the FDA to the combination of PDS0101 and pembrolizumab, an investigational regimen for the treatment of patients with recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma.

In an interview with Targeted Oncology, William J. Catalona, MD, reviewed the history of active surveillance in the prostate cancer space and how the practice has become more widespread in the United States.

The combination of naxitamab combined with irinotecan, temozolomide, and sargramostim induced responses in patients with high-risk neuroblastoma.

In an interview with Targeted Oncology, Neal Shore, MD, FACS, discussed the use of enzalutamide plus androgen deprivation therapy in metastatic hormone sensitive prostate cancer and how post-hoc findings from the ARCHES study can be applied to practice.

In patients with advanced non-squamous non–small cell lung cancer treated within large community health systems in the United States , biomarker testing appeared to be significantly higher compared with independent community practices, research shows.

Dosing of NX-2127 in patients with chronic lymphocytic leukemia has begun in a phase 1b clinical trial.

With an FDA fast track designation in tow, seribantumab is now under investigation in a phase 2 study of patients with advanced solid tumors.

The FDA has granted approval to azacitidine for the treatment of pediatric patients with newly diagnosed juvenile myelomonocytic leukemia following positive phase 2 research.

In an interview with Targeted Oncology™, Siddhartha Mukherjee, MD, examined the current treatment landscape for acute myeloid leukemia and therapies on the horizon.

In an interview with Targeted Oncology, Joaquim Bellmunt, MD, PhD, discussed the long-term overall survival data for first-line maintenance avelumab in mUC presented at the AUA 2022 Annual Meeting and a sub-analysis of the JAVELIN Bladder 100 trial being read out at the upcoming 2022 ASCO Annual Meeting.

In the phase 3 IKEMA study, isatuximab added to carfilzomib and dexamethasone improved progression-free survival in patient with relapsed multiple myeloma.

Findings from a post-hoc analysis of the phase 3 ARAMIS clinical trial shows positive efficacy and consistent safety and tolerability with darolutamide in patients with nonmetastatic castration resistant prostate cancer, despite type of prior local therapy.

In an interview with Targeted Oncology, Wojciech Jurczak, MD, PhD, discussed the clinical trial investigation of ceralasertib with or without acalabrutinib in patients with high-risk relapsed or refractory chronic lymphocytic leukemia.

In an interview with Targeted Oncology, Ping Chi, discussed the novel strategy of combining KIT and MEK inhibition to treat patients with GIST treated in the frontline setting.